Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Eylea biosimilar injunction denial ‘negative’ for Regeneron, says UBS
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Regeneron stock dips as court denies Eylea patent stay
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its ...
Nasdaq25d
FDA Accepts BLA For AVT06, Proposed Biosimilar To Eylea For Retinal Diseases
There are five approved biosimilars for Eylea - Amgen's Pavblu, Sandoz's Enzeevu, Formycon's Ahzantive, Samsung Bioepis' Opuviz and Biocon Biologics' Yesafili. Alvotech is also developing AVT29 ...
Investing18d
Amgen’s SWOT analysis: stock outlook amid pipeline progress and market challenges
The cardiometabolic franchise is expected to expand and entrench its market position. Pavblu, Amgen’s Eylea biosimilar, is well-positioned to compete effectively due to injunctions against other ...